Angle posted a loss before tax of 15.0 million pounds for the year ended 31 December 2024 compared to a loss of 21.6 million pounds, prior year. Loss per share was 4.82 pence compared to a loss of 7.73 pence. Revenue increased to 2.86 million pounds compared to 2.19 million pounds.
ANGLE Chief Executive, Andrew Newland, said: "We entered 2025 with our large pharma contracts either successfully completed or progressing well and are confident that these have the potential to lead to larger scale opportunities."
The company is funded into first quarter, 2026.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback: editorial@rttnews.com